Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors

NCT07182175 | Enrolling By Invitation DMC

• 1 other identifier: 2024yan411-002
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery. The main questions it aims to answer are:

• What heart and blood pressure changes do patients with different types of adrenal tumors have before surgery?
• What factors affect how the heart and blood pressure recover after surgery?
• Do the heart and blood pressure conditions before surgery influence recovery and the risk of heart or brain problems after surgery? Patients will have heart ultrasound checks and health monitoring before and after surgery. The results will help doctors choose the right medicines before surgery, better understand possible risks during the operation, and make safer treatment plans for patients with functional adrenal tumors.

Conditions

Primary Aldosteronism; Adrenal Tumor; Cushing s Syndrome; Pheochromocytoma/Paraganglioma (PPGL)

Outcome Measures

Primary Outcomes (1)

• Recovery of cardiac function after adrenal surgery

  global longitudinal stress

  from enrollment to 4,24,48 weeks after surgery

Secondary Outcomes (1)

• Recovery of blood pressure after adrenal surgery

  from enrollment to 4,24,48 weeks after surgery

Study Arms (3)

primary aldosteronism

Cushing s Syndrome

Pheochromocytoma/Paraganglioma (PPGL)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of patients with functional adrenal tumors who are hospitalized and/or seen in the outpatient clinic of the Department of Urology at Peking University First Hospital.

You may qualify if:

• Patients diagnosed in the Department of Urology, Peking University First Hospital with pheochromocytoma and paraganglioma (PPGL), primary aldosteronism (PA), or Cushing syndrome (CS);
• Written informed consent obtained.

You may not qualify if:

• Patients with PPGL, PA, or CS who receive medication or conservative treatment and are not eligible for surgical resection;
• Patients with communication disorders or severe physical impairments such as aphasia, or visual/hearing disabilities;
• Patients with severe mental illness who cannot cooperate with the study;
• Pregnant women or patients otherwise deemed unsuitable for participation by the investigators.

Sponsors & Collaborators

• Peking University First Hospital: lead

Study Sites (1)

Peking University First Hospital

Beijing, China

Location

MeSH Terms

Conditions

Hyperaldosteronism; Adrenal Gland Neoplasms; Pheochromocytoma; Paraganglioma

Condition Hierarchy (Ancestors)

Adrenocortical Hyperfunction; Adrenal Gland Diseases; Endocrine System Diseases; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 48 Weeks
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 11, 2025
• First Posted: September 19, 2025
• Study Start: September 19, 2024
• Primary Completion: November 17, 2024
• Study Completion (Estimated): May 29, 2026
• Last Updated: September 19, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)